The Department of Health and Social Care has updated its official UK statistics on medicine supply disruptions, covering supplier notifications reported up to June 2026.
The publication records medicine supply issue and discontinuation notifications submitted to the department by pharmaceutical suppliers. It forms part of a twice yearly statistical series intended to give a clearer view of reported pressures affecting the availability of medicines in the UK.
The data is published on GOV.UK under official statistics and corporate reporting material. It covers notifications made by suppliers when they identify a supply problem or when a product is being discontinued. Such notifications are an important part of how government and health bodies monitor risks to medicine availability.
Medicine supply disruption statistics do not necessarily show every problem experienced by patients, pharmacies or hospitals. They are based on information reported by pharmaceutical companies to the Department of Health and Social Care. The figures therefore provide a structured record of supplier notifications rather than a complete measure of every shortage encountered in clinical practice.
Supply issues can arise for several reasons, including manufacturing delays, quality control problems, changes in commercial supply, distribution difficulties or shifts in demand. Discontinuation notifications are separate from temporary supply problems and relate to medicines that suppliers intend to stop providing.
For patients, medicine supply problems can mean delays, changes to prescriptions or the need for clinicians to consider alternative treatments. For pharmacists and prescribers, early information about supply disruption can help with planning, substitution where clinically appropriate and communication with patients who may be affected.
The publication of official statistics also gives researchers, NHS organisations and policy makers a more consistent source of information about reported disruption over time. Regular updates allow changes in the volume and type of notifications to be assessed, although interpretation depends on the detail contained in the statistical release and the reporting behaviour of suppliers.
The Department of Health and Social Care requires information from pharmaceutical suppliers because reliable supply is central to patient care. Medicines used for long term conditions, acute infections, cancer care, mental health treatment and rare diseases can all be affected when supply chains are disrupted, though the impact varies depending on the product and the availability of alternatives.
The latest release is significant because it extends the official record to June 2026. It continues a twice yearly reporting cycle, giving the public and health sector users a scheduled update on medicine supply issue and discontinuation notifications in the UK.
The statistics should be read as part of the wider system for monitoring medicine availability rather than as a direct guide for individual treatment decisions. Patients concerned about a prescription should seek advice from their pharmacist, prescriber or relevant NHS service, as clinical alternatives and local availability can vary.
By maintaining a regular official record, the Department of Health and Social Care provides a public source of information on reported medicine supply disruption and product discontinuations. The June 2026 update adds to that evidence base and supports scrutiny of an issue that can have direct consequences for treatment access and continuity of care.
